J Korean Med Sci.  2025 Mar;40(12):e53. 10.3346/jkms.2025.40.e53.

Psychotropic Drug Use in Korean Patients With Osteoarthritis

• Kang SH
• Kim HA
• Choi I
• Park CM
• Jhang H
• Kim J
• Go DJ
• Jang S

• KMID: 2566258
• DOI: http://doi.org/10.3346/jkms.2025.40.e53

Abstract

Background
There are few safe effective ways to relieve osteoarthritis (OA) pain; as a result, off-label psychotropic drug prescriptions have increased worldwide. This study examined the change in psychotropic drug prescriptions for patients with OA from 2011 to 2020 using the Korean National Health Insurance Service dataset.
Methods
The study population consisted of patients with hip or knee OA aged ≥ 65 years. Psychotropic drugs included opioids, benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), anti-epileptics, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), typical antipsychotics, atypical antipsychotics, and anxiolytics. The prevalence and long-term (> 3 months) prescription rates of psychotropic drugs in OA patients were calculated.
Results
The study included 1,821,158 patients with OA (mean age 71.7 years; 65.32% female). Of the cohort, 49% had comorbidities for which psychotropics were indicated. The prevalence of psychotropic prescriptions decreased from 58.2% to 52.0% in 2018 and then leveled off. The long-term prescription rate remained constant until 2018 and then increased slightly. The most commonly prescribed psychotropics were opioids and long- and short-acting benzodiazepines. The prescription rates of opioids and long-acting benzodiazepines decreased from 2011 to 2020. For those with psychiatric co-morbidities, the prescription rates of anti-epileptics and SNRIs increased, while the prescription rates of anti-epileptics, SSRIs, other antidepressants, and atypical psychotropics increased for those without such co-morbidities. The most commonly prescribed psychotropics were diazepam and alprazolam, excluding tramadol and tramadol–acetaminophen combination. For those with psychiatric co-morbidities, the prescription rates of gabapentin and fentanyl increased, while for those without such co-morbidities, the prescription rates of lorazepam, fentanyl, escitalopram and quetiapine increased.
Conclusion
A significant number of older Korean patients with OA were prescribed psychotropic drugs in the absence of comorbidities requiring such drugs, including drugs that have little effect on OA and unfavorable safety profiles in older adults.

Keyword

Osteoarthritis; Psychotropics; Opioids; Benzodiazepine; Diazepam; Alprazolam; Fentanyl

Figure

• 

  Fig. 1 Prevalent prescription rates of psychotropics.

• 

  Fig. 2 Prescription rates of specific class of psychotropics.TCA = tricyclic antidepressants, SSRI = selective serotonin reuptake inhibitor.

Reference

1. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11):1578–1589. PMID: 31278997.

2. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020; 72(2):149–162. PMID: 31908149.

3. Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis. J Med Econ. 2011; 14(4):497–507. PMID: 21682606.

4. Singh JA. Time-trends in cocaine, hallucinogen, amphetamine, and sedative/anxiolytic/hypnotic use disorder hospitalizations in rheumatic diseases: a national time-trends study. Clin Rheumatol. 2021; 40(7):3007–3014. PMID: 33786691.

5. Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. 2013; 21(9):571–576. PMID: 23996988.

6. Zeng C, Dubreuil M, LaRochelle MR, Lu N, Wei J, Choi HK, et al. Association of tramadol with all-cause mortality among patients with osteoarthritis. JAMA. 2019; 321(10):969–982. PMID: 30860559.

7. Drossman DA, Ruddy J. Improving patient-provider relationships to improve health care. Clin Gastroenterol Hepatol. 2020; 18(7):1417–1426. PMID: 31843593.

8. Park CM, Ryoo S, Choi M, Lee SJ, Yoo JJ, Kim HA. Total knee replacement after arthroscopic meniscectomy in knee osteoarthritis: a nationwide population-based cohort study. J Korean Med Sci. 2023; 38(1):e6. PMID: 36593689.

9. Kim J . Older adults’ perspectives on chronological definition for old age. Korean Journal of Research in Gerontology. 2019; 28(2):109–117.

10. Arden NK, Perry TA, Bannuru RR, Bruyère O, Cooper C, Haugen IK, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021; 17(1):59–66. PMID: 33116279.

11. Thorlund JB, Turkiewicz A, Prieto-Alhambra D, Englund M. Inappropriate opioid dispensing in patients with knee and hip osteoarthritis: a population-based cohort study. Osteoarthritis Cartilage. 2020; 28(2):146–153. PMID: 31669311.

12. DeMik DE, Bedard NA, Dowdle SB, Burnett RA, McHugh MA, Callaghan JJ. Are we still prescribing opioids for osteoarthritis? J Arthroplasty. 2017; 32(12):3578–3582.e1. PMID: 28887019.

13. Bensen GP, Rogers AC, Leifer VP, Edwards RR, Neogi T, Kostic AM, et al. Does gabapentin provide benefit for patients with knee OA? a benefit-harm and cost-effectiveness analysis. Osteoarthritis Cartilage. 2023; 31(2):279–290. PMID: 36414225.

14. Karsdal MA, Tambiah J, Felson D, Ladel C, Nikolov NP, Hodgins D, et al. Reflections from the OARSI 2022 clinical trials symposium: the pain of OA-deconstruction of pain and patient-reported outcome measures for the benefit of patients and clinical trial design. Osteoarthritis Cartilage. 2023; 31(10):1293–1302. PMID: 37380011.

15. Ferreira GE, McLachlan AJ, Lin CC, Zadro JR, Abdel-Shaheed C, O’Keeffe M, et al. Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. BMJ. 2021; 372:m4825. PMID: 33472813.

16. Leaney AA, Lyttle JR, Segan J, Urquhart DM, Cicuttini FM, Chou L, et al. Antidepressants for hip and knee osteoarthritis. Cochrane Database Syst Rev. 2022; 10(10):CD012157. PMID: 36269595.

17. Sofat N, Harrison A, Russell MD, Ayis S, Kiely PD, Baker EH, et al. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis. J Pain Res. 2017; 10:2437–2449. PMID: 29066930.

18. Ohtori S, Inoue G, Orita S, Takaso M, Eguchi Y, Ochiai N, et al. Efficacy of combination of meloxicam and pregabalin for pain in knee osteoarthritis. Yonsei Med J. 2013; 54(5):1253–1258. PMID: 23918578.

19. Appleyard T, Ashworth J, Bedson J, Yu D, Peat G. Trends in gabapentinoid prescribing in patients with osteoarthritis: a United Kingdom national cohort study in primary care. Osteoarthritis Cartilage. 2019; 27(10):1437–1444. PMID: 31276819.

20. van den Driest JJ, Schiphof D, de Wilde M, Bindels PJ, van der Lei J, Bierma-Zeinstra SM. Antidepressant and anticonvulsant prescription rates in patients with osteoarthritis: a population-based cohort study. Rheumatology (Oxford). 2021; 60(5):2206–2216. PMID: 33175150.

21. Yu D, Appleyard T, Cottrell E, Peat G. Co-prescription of gabapentinoids and opioids among adults with and without osteoarthritis in the United Kingdom between 1995 and 2017. Rheumatology (Oxford). 2021; 60(4):1942–1950. PMID: 33159800.

22. Moyo P, Vaillant J, Girard A, Gairola R, Shireman TI, Trivedi AN, et al. Prevalence of opioid and nonopioid pain management therapies among Medicare beneficiaries with musculoskeletal pain conditions from 2016 to 2019. Drug Alcohol Depend. 2023; 248:109930. PMID: 37269776.

23. Kim JR, Byun SJ, Son DS, Kim HA. Correlation between the ratio of physician consultation fees to hourly minimum wage and consultation length: a cross-sectional study of nine countries. BMJ Open. 2022; 12(12):e064369.

24. Kim HA, Kim MG. A survey study on rheumatologist consultation time in Korean hospitals. J Rheum Dis. 2020; 27(1):45–50.